CH EN
x
Search
About Us
Exploring Jiuzhang Biotech
R&D Philosophy

Guided by natural objectivity and respect for the laws of life, we approach diseases from the perspectives of holistic and functional medicine, exploring effective molecules within natural substances.

 

Natural substances (animals, plants, microorganisms, and minerals) have always accompanied human evolution, and human genetic memory allows for the habitual acceptance of effective components in natural substances. Exploring active substances from non-toxic plants to activate the body's immune system and metabolic regulation mechanism for disease treatment is a promising approach and represents the core R&D philosophy of the Jiuzhang Biotech team.

 

Natural medicines, derived directly from non-toxic plants with their original structures as active ingredients, even without modification, are inherently drug-like and harmless to the human body, such as vitamins.

 

Drugs based on the original structures of natural plants, which have been chemically synthesized and modified through chemical means (such as removing toxic functional groups, and modifying or adding pharmacologically active functional groups), have improved clinical efficacy and decreased toxicity and side effects. These drugs remain irreplaceable and are continuously being discovered for new indications, such as aspirin and metformin.

History
R&D Process and Team of CHA Project
-R&D Process and Team of CHA API -R&D Process and Team of CHA for Injection -Clinical Research Progress and Team of CHA for Injection -Strategic Cooperation with IMM
  • 2024

    A pivotal clinical trial titled “Randomized, Controlled, Open-labeled, Multicenter Phase II/III Clinical Research on the Safety and Efficacy of the CHA for Injection for Recurrent Grade IV Glioblastoma (GBM)” is currently underway, and all subjects have been enrolled.

  • 2018

    Officially initiated the “Randomized, Controlled, Open-labeled, Multicenter Phase II/III Clinical Research on the Safety and Efficacy of the CHA for Injection for Recurrent Grade IV Glioblastoma (GBM)”.

    Clinical Trial Registration Number:

    China CTR20181644

    America NCT03758014

  • 2017

    Completed the “Phase I Clinical Trial for Safety, Tolerability, and Pharmacokinetics of CHA for Injection in Treatment of Advanced Malignant Glioma”.

    Clinical Trial Registration Number:

    China CTR20160113

    America NCT02728349

  • 2016

    Completed the “Phase I Clinical Trial to Evaluate Tolerance and Pharmacokinetic Characteristics of CHA for Injection in Subjects with Advanced Cancer”;

    Initiated the “Phase I Clinical Trial for Safety, Tolerability, and Pharmacokinetics of CHA for Injection in Treatment of Advanced Malignant Glioma”;

    The “Phase I/II Clinical Study of Innovative Class 1 New Drug - CHA for Injection” had been supported by the Science and Technology Major Project for “Major New Drug Innovation” during the 13th Five-Year Plan.

  • 2014

    Initiated the “Phase I Clinical Trial to Evaluate the Tolerance and Pharmacokinetic Characteristics of CHA for Injection in Subjects with Advanced Cancer”.

    Clinical Trial Registration Number:

    China CTR20130586

    America NCT02245204

  • 2013

    Obtained clinical approval from the NMPA (formerly CFDA) (Class 1 chemical drug; approval number of CHA for injection: 2013L01855; approval number of CHA API: 2013L01856), indicated for tumor treatment.

  • 2012

    Submitted the clinical trial application of CHA for injection (a novel innovative Class 1 chemical drug) for the treatment of tumors to NMPA (formerly CFDA).

  • 2008

    Pioneered the use of CHA for tumor immunotherapy, marking the first global application of CHA monomer in the treatment of major diseases (cancers, neurological disorders, and autoimmune diseases).

  • 2005

    Conducted preclinical pharmacological and toxicological research on CHA for injection and its API, a globally first Class 1 anticancer drug.

  • 2003

    Completed the pilot-scale process development and quality research of CHA API; obtained the pilot-scale certification; achieved the successful conversion of high-purity CHA into an API for the first time;

    Completed the research on the formulation and process of CHA for injection by using CHA as the raw material, and achieved industrial production.

  • 2001

    Completed the small-scale process research of CHA API and initiated quality research.

  • 2000

    Started planning the research on extracting CHA monomers for medicinal use from natural plants.

  • 1999

    Jiuzhang Biotech was founded with a focus on the deep exploration and research of small molecule compounds of natural plants.

product
Projects and Products
CHA for injection（Class 1 new chemical drug）
Mechanism research Clinical research Characteristic Application area
Broad anti-tumor spectrum, covering multiple types of diseases
Extending survival period of cancer patients beyond expectations
Good Safety
Combined application available
Early tumor treatment
Enhanced quality of life
No drug resistance
Broad anti-tumor spectrum, covering multiple types of diseases

It is broadly effective against glioma, lung squamous cell carcinoma, esophageal squamous cell carcinoma, cervical squamous cell carcinoma, oral squamous cell carcinoma, colorectal cancer, and other types of cancer.

Based on the research of mechanism, it can be used for the treatment of multiple types of diseases, such as autoimmune diseases and metabolic disorders.

Extending survival period of cancer patients beyond expectations

Patients who live a normal life for over 10 years include:

Patients of tongue squamous cell carcinoma, lung squamous cell carcinoma, and glioblastoma with postoperative recurrence, etc.;

Patients who still live a normal life after early interventional treatment include: patients with small-cell lung cancer, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, etc.

For more details, please refer to the “Diseases and Treatments” section.

Good Safety

Clinical data indicates excellent safety, with no other drug-related adverse reactions besides muscle induration at the injection site.

Combined application available

It demonstrates synergistic effects and toxicity attenuation when combined with multiple chemotherapeutic agents, targeted therapies, and immunotherapeutic agents.

Early tumor treatment

Mechanism studies have shown that CHA is more effective in the early treatment of tumors.

Enhanced quality of life

Improving quality of life for the patients with increased KPS values

No drug resistance

Exerting anti-tumor effects by multi-target, multi-level

Inhibiting mtACAT1 phosphorylation

Releasing immuno-suppression to stimulate immunity

Inducing tumor cell differentiation

CHA for injection
Neurological
disorders
Tumors
Improvement of
biological
functions
Autoimmune
diseases
Antioxidant
effects
Chronic
diseases
Nervous system disorders
Cerebrovascular diseases, Alzheimer’s disease, Parkinson’s disease, etc.
Improvement of biological functions
Liver and kidney function damage (massive hepatic necrosis)
Antioxidant effects
Promoting metabolism and delaying aging
Tumor
Anti-tumor and relief of cancer pain
Autoimmune diseases
Psoriasis, ulcerative colitis, multiple sclerosis, etc.
Chronic diseases
Hyperlipidemia and liver cirrhosis
Treatment
Disease Treatment & Research
Tumor

Glioma

Lung squamous cell carcinoma

Esophageal squamous cell carcinoma

Cervical squamous cell carcinoma

Autoimmune Diseases

Psoriasis

Systemic lupus erythematosus (middle and early stages)

Other Diseases

Alzheimer’s disease

Massive hepatic necrosis

Liver cirrhosis

Hyperlipidemia

partners
International Partner
Miskawaan Health Group (MHG) has fully cooperated with Jiuzhang Biotech

An Asia-Pacific branch of MHG, located in Bangkok and Koh Samui coastline in Thailand, is equipped with Germany's top medical testing and treatment equipment. It is led by Germany's top physicians and primarily serves for the high-net-worth individuals in Europe and America. MHG, specializing in natural therapy, functional medicine and integrative medicine, provides optimum customized cancer prevention and treatment schemes which are suitable for people who have needs such as catering to those seeking medical aesthetics, longevity, holistic health, and tumor prevention and treatment. 

NEWS
News
Dedicated to the in-depth research and development of innovative drugs derived from small molecule compounds of natural plants